Literature DB >> 21160834

Intraductal papillary mucinous neoplasm: Coming of age.

Charles M Vollmer1, Elijah Dixon.   

Abstract

Intraductal papillary mucinous neoplasm (IPMN) is a disease in evolution. Since its first description almost 30 years ago, a better understanding of the disease has steadily accrued. Yet, there are numerous challenges still for clinicians who treat this fascinating disease. A group of leading content experts on IPMN was assembled and charged with presenting cutting-edge knowledge on various topics for which they have considerable experience. This manuscript provides an historical perspective of both clinical and biological quandaries that have been resolved to date. Furthermore, it poses new avenues for investigation while highlighting the contributions of the various authors to this collective review.

Entities:  

Keywords:  Intraductal papillary mucinous neoplasm; Natural history; Pancreatic surgery

Year:  2010        PMID: 21160834      PMCID: PMC2999208          DOI: 10.4240/wjgs.v2.i10.299

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  12 in total

1.  Extent of surgical resections for intraductal papillary mucinous neoplasms.

Authors:  Stefano Crippa; Stefano Partelli; Massimo Falconi
Journal:  World J Gastrointest Surg       Date:  2010-10-27

2.  Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and molecular biology.

Authors:  Caroline S Verbeke
Journal:  World J Gastrointest Surg       Date:  2010-10-27

3.  Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Roberto Salvia; Stefano Crippa; Stefano Partelli; Giulia Armatura; Giuseppe Malleo; Marina Paini; Antonio Pea; Claudio Bassi
Journal:  World J Gastrointest Surg       Date:  2010-10-27

4.  Intraductal papillary mucinous neoplasm and the pancreatic incidentaloma.

Authors:  Tara S Kent; Charles M Vollmer; Mark P Callery
Journal:  World J Gastrointest Surg       Date:  2010-10-27

5.  Diagnostic and therapeutic endoscopic approaches to intraductal papillary mucinous neoplasm.

Authors:  Brian G Turner; William R Brugge
Journal:  World J Gastrointest Surg       Date:  2010-10-27

6.  Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients.

Authors:  Saboor Khan; Guido Sclabas; Kaye M Reid-Lombardo
Journal:  World J Gastrointest Surg       Date:  2010-10-27

7.  Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Jaime Benarroch-Gampel; Taylor S Riall
Journal:  World J Gastrointest Surg       Date:  2010-10-27

8.  Differentiating intraductal papillary mucinous neoplasms from other pancreatic cystic lesions.

Authors:  Steven C Cunningham; Ralph H Hruban; Richard D Schulick
Journal:  World J Gastrointest Surg       Date:  2010-10-27

9.  Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Adam C Yopp; Peter J Allen
Journal:  World J Gastrointest Surg       Date:  2010-10-27

10.  Natural history of intraductal papillary mucinous neoplasia: How much do we really know?

Authors:  Chad G Ball; Thomas J Howard
Journal:  World J Gastrointest Surg       Date:  2010-10-27
View more
  3 in total

1.  Decision-Making for the Management of Cystic Lesions of the Pancreas: How Satisfied Are Patients with Surgery?

Authors:  Priya M Puri; Ammara A Watkins; Tara S Kent; Laura Maggino; Jenna Gates Jeganathan; Mark P Callery; Jeffrey A Drebin; Charles M Vollmer
Journal:  J Gastrointest Surg       Date:  2017-09-05       Impact factor: 3.452

Review 2.  [Diagnostic strategy and differential therapeutic approach for cystic lesions of the pancreas].

Authors:  P Mayer; C Tjaden; M Klauß
Journal:  Radiologe       Date:  2016-04       Impact factor: 0.635

3.  Using Endoscopic Optical Coherence Tomography to Detect and Treat Early-Stage Pancreatic Cancers.

Authors:  Lanchun Lu; Zhilin Hu; Wendy Frankel; Rulong Shen; Wei Chen; Xueliang Pan; John C Grecula; Mark P Bloomston; Mary E Dillhoff
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.